相关实验视频
Updated: Jun 12, 2025

07:07
A Melanoma Patient-Derived Xenograft Model
Published on: May 20, 2019
12.3K
在单细胞水平上对黑色素瘤治疗药物的治疗耐药性
Lijun Yao1,2, Bradley A Krasnick3, Ye Bi3
1Department of Medicine, Washington University in St. Louis, St. Louis, MO, 63110, USA.
Scientific reports
|September 19, 2024
概括
研究人员使用单细胞RNA图谱研究了黑色素瘤的进展和对BRAF-MEK向治疗的耐药性. 他们确定ALDOA和PGK1是耐药细胞中的关键标,建议甲胺作为潜在的治疗方法.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 翻译医学是一种翻译医学.
背景情况:
- BRAF-MEK向疗法彻底改变了晚期黑色素瘤的治疗方法.
- 然而,大多数患者 (80%) 在5年内经历疾病进展.
- 了解黑色素瘤的进展和治疗耐药性至关重要.
研究的目的:
- 调查黑色素瘤进展和治疗耐药性的机制.
- 创建一个全面的单细胞RNA马拉松黑色素瘤瘤在整个治疗的频谱.
- 确定治疗耐药黑色素瘤的新型治疗点.
主要方法:
- 创建了一个单细胞RNA (scRNA) 地图,包含来自18名患者瘤的128,230个细胞.
- 分析了转录组资料,以了解细胞异质性和起源.
- 来自患者瘤的确立的抗BRAF-MEK治疗耐药细胞系.
- 在耐药人群中研究基因表达,并测试了甲福林的疗效.
主要成果:
- 黑色素瘤细胞按患者来源的转录基因组概况聚集在一起.
- 1q和7q的增加被确定为转移性黑色素瘤中潜在的早期克隆事件.
- 在体外传播过程中,PD1-响应的瘤部分丢失了.
- 在耐治疗细胞中,ALDOA和PGK1的表达高.
- 甲胺证明了对抗抗性黑色素瘤细胞的有效性.
结论:
- 对患者瘤和衍生细胞系的单细胞分析对于了解黑色素瘤至关重要.
- 识别耐药性机制可以指导开发更有效的疗法.
- 用甲胺准ALDOA和PGK1显示出克服BRAF-MEK抑制剂耐药性的希望.
相关概念视频
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Skin Cancer
4.0K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
4.0K
Tumor Immunotherapy
491
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
491

